Zymuphen MP-Activity Assay from Hyphne Biomed
FOR IMMEDIATE RELEASE:
A Revolution in Hemostasis Testing:
Measure Procoagulant Microparticle Activity
Mason, OH, February 1, 2007 — Aniara Corporation introduces the Zymuphen MPActivity assay for measurement of pro-coagulant microparticles in plasma.
Procoagulant microparticles, generated by activation of blood cells such as platelets, endothelial cells, and leucocytes can be observed at high levels in certain pathological conditions. Zymutest MP-Activity assay from Hyphen BioMed is the first quantitative functional assay, complete with calibrators and controls. Microparticles present in plasma bind to Annexin V that has been immobilized in microwells and then expose their phospholipid surface. This allows FXa-FVa, in the presence of calcium, to activate prothrombin to thrombin, which is detected using a thrombin sensitive chromogenic substrate. The amount of pro-coagulant activity due to the presence of microparticles is proportional to the amount of thrombin generated.
The assay is optimized for routine use and available in a convenient microplate format, with results in 90 minutes.
Zymuphen MP-Activity assay is for research use only in the U.S. and Canada.
Aniara Corporation. continues to bring innovative hemostasis products to research,
clinical and specialty laboratories. Contact Aniara Corporation at (513) 770-1991 or
Put Us to the Test!
Contact: Jonas Kingo, VP
Company Name: Aniara Corporation.
Telephone Number: 513-770-1991
Email Address: email@example.com
Web site address: www.aniara.com
- Contact Information
- Jonas Kingo
- Aniara Corporation
- Contact via E-mail
This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.
News Release Distribution and Press Release Distribution Services Provided by WebWire.